$122.50
1.361.12%
At Close: -
$122.50
00.00%
After Hours: 5:41 PM EDT
15 minutes delayed
Comments
Loading...
Moderna
MRNANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Moderna (NASDAQ:MRNA) Stock, Analyst Ratings, Price Targets, Forecasts
Moderna Inc has a consensus price target of $166.95 based on the ratings of 25 analysts. The high is $404 issued by Barclays on November 5, 2021. The low is $86 issued by HSBC on February 26, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Evercore ISI Group, and Oppenheimer on June 27, 2024, June 27, 2024, and June 12, 2024, respectively. With an average price target of $171 between Piper Sandler, Evercore ISI Group, and Oppenheimer, there's an implied 39.59% upside for Moderna Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Evercore ISI Group
Oppenheimer
RBC Capital
UBS
1calculated from analyst ratings
Analyst Ratings for Moderna
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 06/27/2024 | Buy Now | 74.69% | Piper Sandler | Edward Tenthoff | $214 → $214 | Reiterates | Overweight → Overweight | Get Alert |
| 06/27/2024 | Buy Now | -2.04% | Evercore ISI Group | Cory Kasimov | $120 → $120 | Maintains | In-Line | Get Alert |
| 06/12/2024 | Buy Now | 46.12% | Oppenheimer | Hartaj Singh | $163 → $179 | Maintains | Outperform | Get Alert |
| 06/03/2024 | Buy Now | 30.61% | RBC Capital | Luca Issi | $135 → $160 | Maintains | Outperform | Get Alert |
| 06/03/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 05/14/2024 | Buy Now | -2.04% | Evercore ISI Group | Cory Kasimov | → $120 | Initiates | → In-Line | Get Alert |
| 05/07/2024 | Buy Now | 23.27% | UBS | Eliana Merle | $143 → $151 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | -13.47% | Canaccord Genuity | Bill Maughan | $91 → $106 | Maintains | Hold | Get Alert |
| 05/03/2024 | Buy Now | 10.2% | RBC Capital | Luca Issi | $125 → $135 | Maintains | Outperform | Get Alert |
| 05/03/2024 | Buy Now | 33.06% | Oppenheimer | Hartaj Singh | $142 → $163 | Maintains | Outperform | Get Alert |
| 05/02/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 04/11/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 04/09/2024 | Buy Now | 2.04% | Jefferies | Michael Yee | → $125 | Reiterates | Buy → Buy | Get Alert |
| 03/28/2024 | Buy Now | 2.04% | RBC Capital | Luca Issi | → $125 | Reiterates | Outperform → Outperform | Get Alert |
| 03/28/2024 | Buy Now | — | Needham | Joseph Stringer | — | Reiterates | → Hold | Get Alert |
| 02/26/2024 | Buy Now | -29.8% | HSBC | Yifeng Liu | $75 → $86 | Downgrade | Hold → Reduce | Get Alert |
| 02/23/2024 | Buy Now | 2.04% | RBC Capital | Luca Issi | → $125 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | Buy Now | -25.71% | Canaccord Genuity | Bill Maughan | $82 → $91 | Maintains | Hold | Get Alert |
| 01/12/2024 | Buy Now | 2.04% | RBC Capital | Luca Issi | → $125 | Reiterates | Outperform → Outperform | Get Alert |
| 01/02/2024 | Buy Now | 15.92% | Oppenheimer | Hartaj Singh | → $142 | Upgrade | Perform → Outperform | Get Alert |
| 12/01/2023 | Buy Now | -26.53% | JP Morgan | Jessica Fye | $93 → $90 | Maintains | Neutral | Get Alert |
| 11/29/2023 | Buy Now | -33.06% | Canaccord Genuity | Bill Maughan | → $82 | Initiates | → Hold | Get Alert |
| 11/03/2023 | Buy Now | 2.04% | RBC Capital | Luca Issi | $180 → $125 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 88.57% | Goldman Sachs | Salveen Richter | $269 → $231 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | -43.67% | HSBC | Yifeng Liu | $89 → $69 | Upgrade | Reduce → Hold | Get Alert |
| 11/02/2023 | Buy Now | — | Deutsche Bank | Emmanuel Papadakis | — | Downgrade | Hold → Sell | Get Alert |
| 09/13/2023 | Buy Now | 14.29% | Argus Research | Jasper Hellweg | $160 → $140 | Maintains | Buy | Get Alert |
| 08/04/2023 | Buy Now | 0.41% | Morgan Stanley | Matthew Harrison | $128 → $123 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 22.45% | B of A Securities | Geoff Meacham | $175 → $150 | Maintains | Neutral | Get Alert |
| 08/04/2023 | Buy Now | 55.1% | RBC Capital | Luca Issi | $200 → $190 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 2.04% | TD Cowen | Tyler Van Buren | $145 → $125 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/03/2023 | Buy Now | 2.04% | Deutsche Bank | Emmanuel Papadakis | $200 → $125 | Downgrade | Buy → Hold | Get Alert |
| 07/24/2023 | Buy Now | 34.69% | TD Cowen | Tyler Van Buren | $175 → $165 | Maintains | Outperform | Get Alert |
| 07/24/2023 | Buy Now | — | William Blair | Myles Minter | — | Initiates | → Market Perform | Get Alert |
| 07/14/2023 | Buy Now | -20.82% | HSBC | Rajesh Kumar | → $97 | Initiates | → Reduce | Get Alert |
| 07/11/2023 | Buy Now | 4.49% | Morgan Stanley | Matthew Harrison | $153 → $128 | Maintains | Equal-Weight | Get Alert |
| 06/26/2023 | Buy Now | 55.92% | UBS | Eliana Merle | $221 → $191 | Upgrade | Neutral → Buy | Get Alert |
| 05/05/2023 | Buy Now | 57.55% | Morgan Stanley | Matthew Harrison | $185 → $193 | Maintains | Equal-Weight | Get Alert |
| 04/26/2023 | Buy Now | — | Guggenheim | Evan Wang | — | Initiates | → Neutral | Get Alert |
| 04/12/2023 | Buy Now | 14.29% | JP Morgan | Jessica Fye | $145 → $140 | Maintains | Neutral | Get Alert |
| 04/10/2023 | Buy Now | 18.37% | JP Morgan | Jessica Fye | $127 → $145 | Maintains | Neutral | Get Alert |
| 03/13/2023 | Buy Now | 46.94% | TD Cowen | Tyler Van Buren | $150 → $180 | Upgrade | Market Perform → Outperform | Get Alert |
| 03/02/2023 | Buy Now | 63.27% | RBC Capital | Luca Issi | → $200 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | 63.27% | Deutsche Bank | Emmanuel Papadakis | $225 → $200 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | -24.08% | SVB Leerink | Mani Foroohar | $111 → $93 | Downgrade | Market Perform → Underperform | Get Alert |
| 02/08/2023 | Buy Now | 12.65% | JP Morgan | Jessica Fye | $132 → $138 | Maintains | Neutral | Get Alert |
| 01/25/2023 | Buy Now | 22.45% | Cowen & Co. | Tyler Van Buren | $130 → $150 | Maintains | Market Perform | Get Alert |
| 01/24/2023 | Buy Now | 67.35% | Morgan Stanley | Matthew Harrison | $209 → $205 | Maintains | Equal-Weight | Get Alert |
| 01/18/2023 | Buy Now | -9.39% | SVB Leerink | Mani Foroohar | $102 → $111 | Maintains | Market Perform | Get Alert |
| 01/18/2023 | Buy Now | 69.8% | Chardan Capital | Geulah Livshits | $191 → $208 | Maintains | Neutral | Get Alert |
| 12/20/2022 | Buy Now | 77.14% | Piper Sandler | Edward Tenthoff | $214 → $217 | Maintains | Overweight | Get Alert |
| 12/19/2022 | Buy Now | 124.49% | Jefferies | Michael Yee | $170 → $275 | Upgrade | Hold → Buy | Get Alert |
| 12/16/2022 | Buy Now | 70.61% | Morgan Stanley | Matthew Harrison | $170 → $209 | Maintains | Equal-Weight | Get Alert |
| 12/14/2022 | Buy Now | 55.92% | Chardan Capital | Geulah Livshits | $186 → $191 | Downgrade | Buy → Neutral | Get Alert |
| 12/13/2022 | Buy Now | -16.73% | SVB Leerink | Mani Foroohar | $101 → $102 | Maintains | Market Perform | Get Alert |
| 11/07/2022 | Buy Now | 51.84% | Chardan Capital | Geulah Livshits | $188 → $186 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 38.78% | Morgan Stanley | Matthew Harrison | $175 → $170 | Maintains | Equal-Weight | Get Alert |
| 10/24/2022 | Buy Now | -0.41% | JP Morgan | Jessica Fye | $165 → $122 | Maintains | Neutral | Get Alert |
| 10/21/2022 | Buy Now | -17.55% | SVB Leerink | Mani Foroohar | $74 → $101 | Upgrade | Underperform → Market Perform | Get Alert |
| 10/18/2022 | Buy Now | 42.86% | Morgan Stanley | Matthew Harrison | $197 → $175 | Maintains | Equal-Weight | Get Alert |
| 10/13/2022 | Buy Now | 141.63% | Goldman Sachs | Salveen Richter | $290 → $296 | Maintains | Buy | Get Alert |
| 09/14/2022 | Buy Now | 22.45% | Argus Research | Jasper Hellweg | $180 → $150 | Maintains | Buy | Get Alert |
| 09/08/2022 | Buy Now | 34.69% | Deutsche Bank | Emmanuel Papadakis | $155 → $165 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2022 | Buy Now | 60.82% | Morgan Stanley | Matthew Harrison | $199 → $197 | Maintains | Equal-Weight | Get Alert |
| 08/04/2022 | Buy Now | -39.59% | SVB Leerink | Mani Foroohar | $77 → $74 | Maintains | Underperform | Get Alert |
| 08/01/2022 | Buy Now | -37.14% | SVB Leerink | Mani Foroohar | $70 → $77 | Maintains | Underperform | Get Alert |
| 06/07/2022 | Buy Now | -42.86% | SVB Leerink | Mani Foroohar | $80 → $70 | Maintains | Underperform | Get Alert |
| 05/18/2022 | Buy Now | 74.69% | Piper Sandler | Edward Tenthoff | $348 → $214 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 62.45% | Morgan Stanley | Matthew Harrison | $217 → $199 | Maintains | Equal-Weight | Get Alert |
| 04/12/2022 | Buy Now | 77.14% | Morgan Stanley | Matthew Harrison | $205 → $217 | Maintains | Equal-Weight | Get Alert |
| 03/25/2022 | Buy Now | -34.69% | SVB Leerink | Mani Foroohar | $81 → $80 | Maintains | Underperform | Get Alert |
| 03/07/2022 | Buy Now | 26.53% | Deutsche Bank | Emmanuel Papadakis | $175 → $155 | Maintains | Hold | Get Alert |
| 02/28/2022 | Buy Now | 67.35% | Morgan Stanley | Matthew Harrison | $213 → $205 | Maintains | Equal-Weight | Get Alert |
| 02/25/2022 | Buy Now | -33.88% | SVB Leerink | Mani Foroohar | $85 → $81 | Maintains | Underperform | Get Alert |
| 02/01/2022 | Buy Now | 73.88% | Morgan Stanley | Matthew Harrison | $315 → $213 | Maintains | Equal-Weight | Get Alert |
| 01/28/2022 | Buy Now | -30.61% | SVB Leerink | Mani Foroohar | $86 → $85 | Maintains | Underperform | Get Alert |
| 01/26/2022 | Buy Now | 42.86% | Deutsche Bank | Emmanuel Papadakis | → $175 | Upgrade | Sell → Hold | Get Alert |
| 01/21/2022 | Buy Now | 80.41% | UBS | Eliana Merle | → $221 | Initiates | → Neutral | Get Alert |
| 01/21/2022 | Buy Now | 46.94% | B of A Securities | Geoff Meacham | $135 → $180 | Upgrade | Underperform → Neutral | Get Alert |
| 01/18/2022 | Buy Now | 157.14% | Morgan Stanley | Matthew Harrison | $313 → $315 | Maintains | Equal-Weight | Get Alert |
| 12/07/2021 | Buy Now | 104.08% | Cowen & Co. | Tyler Van Buren | — | Initiates | → Market Perform | Get Alert |
| 11/09/2021 | Buy Now | 148.16% | Wolfe Research | — | — | Initiates | → Outperform | Get Alert |
| 11/05/2021 | Buy Now | -29.8% | SVB Leerink | Mani Foroohar | — | Maintains | Underperform | Get Alert |
| 11/05/2021 | Buy Now | 229.8% | Barclays | Gena Wang | — | Maintains | Overweight | Get Alert |
| 11/05/2021 | Buy Now | 155.51% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 11/05/2021 | Buy Now | 165.31% | Jefferies | Michael Yee | — | Maintains | Hold | Get Alert |
| 11/05/2021 | Buy Now | 222.45% | Goldman Sachs | Salveen Richter | — | Maintains | Buy | Get Alert |
| 10/22/2021 | Buy Now | 104.08% | Deutsche Bank | — | — | Initiates | → Sell | Get Alert |
| 10/15/2021 | Buy Now | — | Piper Sandler | Edward Tenthoff | — | Upgrade | Neutral → Overweight | Get Alert |
| 09/07/2021 | Buy Now | 175.1% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 08/06/2021 | Buy Now | 277.96% | Barclays | Gena Wang | — | Maintains | Overweight | Get Alert |
| 08/06/2021 | Buy Now | — | Oppenheimer | Hartaj Singh | — | Downgrade | Outperform → Perform | Get Alert |
| 08/06/2021 | Buy Now | 263.27% | Piper Sandler | Edward Tenthoff | — | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for Moderna (MRNA) stock?
The latest price target for Moderna (NASDAQ:MRNA) was reported by Needham on June 28, 2024. The analyst firm set a price target for $0.00 expecting MRNA to fall to within 12 months (a possible -100.00% downside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Moderna (MRNA)?
The latest analyst rating for Moderna (NASDAQ:MRNA) was provided by Needham, and Moderna reiterated their hold rating.
When was the last upgrade for Moderna (MRNA)?
The last upgrade for Moderna Inc happened on January 2, 2024 when Oppenheimer raised their price target to $142. Oppenheimer previously had a perform for Moderna Inc.
When was the last downgrade for Moderna (MRNA)?
The last downgrade for Moderna Inc happened on February 26, 2024 when HSBC changed their price target from $75 to $86 for Moderna Inc.
When is the next analyst rating going to be posted or updated for Moderna (MRNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moderna, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moderna was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Moderna (MRNA) correct?
While ratings are subjective and will change, the latest Moderna (MRNA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Moderna (MRNA) is trading at is $122.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.